The Canadian market size for Penicillins and Streptomycins in dosage form has experienced a notable transformation from 2013 to 2023. The value per capita fell from $7.87 in 2013 to a low of $5.16 in 2019, indicating a significant downward trend. However, from 2020 onwards, there was a recovery, with values rising to $7.4 per capita by 2023. The year-on-year variations show a return to growth, particularly noticeable with the gains post-2020. Over the last five years, the compound annual growth rate (CAGR) reflects a resurgence in value, following earlier declines.
Looking forward, key trends to watch include potential impacts of policy changes in Canada related to antibiotic prescription practices and emerging resistance to these treatments, which could influence both demand and market value dynamics in the coming years.
| # | 31 Countries | US Dollars Per Capita | Last Year | |||
|---|---|---|---|---|---|---|
| 1 | 1 Italy | 11.76 | 2023 | View data | ||
| 2 | 2 New Zealand | 11.59 | 2023 | View data | ||
| 3 | 3 France | 11.21 | 2023 | View data | ||
| 4 | 4 Belgium | 11.17 | 2023 | View data | ||
| 5 | 5 United Kingdom | 10.77 | 2023 | View data | ||
| 6 | 6 Australia | 10.14 | 2023 | View data | ||
| 7 | 7 Canada | 7.4 | 2023 | |||
| 8 | 8 Germany | 5.7 | 2023 | View data | ||
| 9 | 9 Switzerland | 5.65 | 2023 | View data | ||
